Table 4.

Physiological, cognitive, and subjective responses in buprenorphine-maintained and control participants to atazanavir (400 mg daily) or atazanavir/ritonavir (300/100 mg daily)

	Atazanavir Buprenorphine N=10	Atazanavir Control N = 10	Atazanavir/Ritonavir Buprenorphine N = 10	Atazanavir/Ritonavir Control N = 10
AST Pre/Post (U/L)	23.2 (1.5)/25.5 (4.6)	19.1 (1.2)/18.8 (2.5)	20.4 (2.0)/19.1 (1.4)	22.2 (1.3)/17.0 (1.3)
				p=.012
ALT Pre/Post (U/L)	24.0 (5.4)/23.0 (6.5)	18.4 (3.9)/18.3 (4.1)	19.4 (4.3)/18.2 (3.8)	22.4 (4.0)/18.3 (3.2)
Total Bilirubin Pre/Post (mg/dL)	0.5 (0.1)/1.1 (0.2)	0.6 (0.1)/1.7 (0.2)	0.4 (0.1)/1.8 (0.4)	0.6 (0.1)/2.9 (0.3)
	p=.003	p=.001	p=.005	p<.001
Direct Bilirubin Pre/Post (mg/dL)	0.1 (0.01)/0.2 (0.02)	0.1 (0.03)/0.2 (0.03)	0.1 (0.01)/0.3 (0.05)	0.1 (0.01)/0.4 (0.04)
	p=.001	p=.005	p=.006	p<.0001
PR Interval Pre/Post (ms)	159.8 (6.3)/168.4 (8.0)	163.0 (5.3)/176.0 (4.5)	177.0 (10.4)/182.2 (13.0)	156.2 (6.1)/166.2 (6.3)
		p=.020		p=.014
QTc Interval Pre/Post (ms)	409.0 (5.4)/410.3 (3.8)	417.0 (6.7)/405.2 (10.3)	406.8 (3.5)/408.4 (4.9)	419.4 (5.2)/407.8 (3.4)
				p=.028
OOWS Pre/Post	0.1 (0.1)/0.0 (0.0)	0.0 (0.0)/0.0 (0.0)	0.0 (0.0)/0.0 (0.0)	0.0 (0.0)/0.0 (0.0)
MMSE Pre/Post	29.3 (0.3)/29.8 (0.1)	29.6 (0.2)/29.4 (0.2)	29.5 (0.2)/29.5 (0.2)	29.5 (0.2)/29.4 (0.3)
	p=.052
Adverse Symptoms Total Score Pre/Post	9.9 (3.1)/6.9 (1.6)	1.3 (0.8)/0.7 (0.5)	7.5 (2.6)/6.5 (1.7)	0.0 (0.0)/1.1 (0.7)
Drowsy/Sleepy Score Pre/Post	0.7 (0.25)/0.5(0.25)	0.2(0.13)/0.1(0.09)	0.1(0.09)/0.6(0.25)	0.0(0.0)/0.2(0.19)

* Mean (SE)

p values are shown for comparisons where significant differences were observed